Elutia (NASDAQ:ELUT) Rating Reiterated by Cantor Fitzgerald

Elutia (NASDAQ:ELUT)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They currently have a $8.00 price objective on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 406.30% from the company’s current price.

Elutia Trading Up 27.4 %

Shares of ELUT traded up $0.34 during trading hours on Tuesday, reaching $1.58. 12,161,354 shares of the company traded hands, compared to its average volume of 192,386. Elutia has a 12 month low of $1.10 and a 12 month high of $9.01. The firm has a market capitalization of $25.68 million, a price-to-earnings ratio of -0.72 and a beta of -0.09.

About Elutia

Elutia Inc, a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. It offers CanGaroo Envelope, which is used for the stabilization of implantable cardiac devices, such as pacemakers and defibrillators. The company also engages in the development of CanGaroo RM for delivery directly to the surgical site.